Neurocrine Biosciences and Takeda Amend Partnership to Develop and Commercialize Osavampator in Japan
Shots:
- Neurocrine & Takeda have revised their 2020 collaboration to develop & commercialize osavampator (NBI-1065845/TAK-653), which originally granted Neurocrine exclusive license to osavampator, NBI-1070770, & the GPR139 antagonist program
- As per the amendment, Neurocrine will get exclusive rights to develop & market osavampator to treat major depressive disorder (MDD) globally, while Takeda will reacquire the rights in Japan; both will share development cost in their respective regions and eligible to receive royalties
- Osavampator is an AMPA positive allosteric modulator developed by Neurocrine & Takeda to treat MDD. Following the FDA meeting on the P-II (SAVITRI) trial, a P-III trial will begin in H1’25
Ref: Prnewswire | Image: Neurocrine & Takeda
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
